Phase II Trial of Erlotinib in Advanced Pancreatic Cancer

Sponsor
University Health Network, Toronto
Study ID
NCT00497224
Phase
PHASE2
Status
Completed

Conditions

  • Cancer
  • Pancreas

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Erlotinib — DRUG
    Erlotinib starting at 150 mg PO (by mouth) daily. Dose may increase or decrease by the study doctor as per protocol (study plan).

Study Details

This is an open-label, multi-center phase II study of erlotinib in patients with metastatic or locally advanced, unresectable pancreatic cancer who have received up to one line of gemcitabine based chemotherapy.

Key Dates

First listed
Jul 6, 2007
Start date
Nov 30, 2006
Status verified
May 2019
Primary completion
Dec 31, 2008
Completion
Jun 30, 2013

Study Design

Enrollment
51 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Erlotinib
    Eligible patients will receive erlotinib 150mg PO daily, with dose escalation occurring as tolerated.

Primary Outcome Measure

Objective Response Rate [ Time Frame: Clinically assessed every cycle (month) and radiologically assessed every 2 cycles (2 months) with CT scan ]

Related Studies